Ruxandra Draghia-Akli - Nov 11, 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Section 16
Signature
/s/Mark J. Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Nov 11, 2024
Transactions value $
$577,992
Form type
4
Date filed
11/13/2024, 04:08 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Award $578K +64.2K $9.01 64.2K Nov 11, 2024 Common Stock 64.2K $9.01 Direct F1
transaction NVAX Restricted Stock Units Award $0 +42.8K $0.00 42.8K Nov 11, 2024 Common Stock 42.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.
F3 One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date.